Partial
Mostly Aligned
Patient Risk:
Low
Summary
Partial alignment. Packaging-related claims (strength and XR designation) are supported, but the majority of user-provided claims about E 56, manufacturer diversity, and inter-brand considerations are not directly supported by the provided label excerpt. Notably, critical safety and applicability information is not addressed by the extracted claims.
Category Scores
Accurate Statements
The packaging for quetiapine extended-release tablets shows the strength (mg) and release designation (XR).
16 How Supplied
Unsupported Statements
Quetiapine is marketed by multiple companies under brand and generic versions.
Not present in the provided label excerpt (16 How Supplied).
E 56 usually refers to a specific quetiapine tablet strength/form.
Not present in the provided label excerpt.
E 56 can correspond to different doses (for example, quetiapine 50 mg/56 mg) depending on local labeling.
Not present in the provided label excerpt.
The exact manufacturer list depends on the country and the specific product code on the package.
Not present in the provided label excerpt.
The box/bottle for a given quetiapine E 56 product shows the active ingredient wording (quetiapine fumarate vs quetiapine).
Label shows 'Quetiapine extended-release tablets, USP' but does not specify fumarate salt form.
The manufacturer name (often labeled as 'manufactured by' or 'marketed by') is on the packaging.
Not present in the provided label excerpt.
To identify the 'other manufacturers' for your exact 'E 56' product, check the packaging for the strength, release type, active ingredient wording, and manufacturer name.
This guidance goes beyond the specific label text provided.
Brand and generic manufacturers are interchangeable only if the generic has the same active ingredient (quetiapine and the same salt form, if specified), strength, release type, and dosing instructions.
Not present in the provided label excerpt.
Switching between brands or generics with different release profiles can change how the drug is absorbed.
Not present in the provided label excerpt.
Any changes in manufacturer should be confirmed with your pharmacist.
Not present in the provided label excerpt.
DrugPatentWatch focuses on patent and exclusivity status rather than listing every current tablet manufacturer for a specific strength code.
Not present in the provided label excerpt.
I can use DrugPatentWatch to identify the key IP/patent landscape for quetiapine, but it likely won’t replace checking the label/manufacturer for 'E 56'.
Not present in the provided label excerpt.
Sources are limited to DrugPatentWatch quetiapine patent/exclusivity pages.
Not present in the provided label excerpt.
Contradictions
Important Omissions
Critical safety information is not addressed by these packaging-focused claims. Important safety elements exist in labeling (e.g., boxed warnings, contraindications, pregnancy and pediatric use, dosing safety) that are not captured by the 'E 56' packaging-specific statements.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Evaluation centers on packaging statements; substantial safety content (boxed warnings, contraindications, pregnancy/pediatric use, monitoring) is not addressed by the claims examined.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Limit claims to what is present on the label; avoid asserting country-specific manufacturer details or internal codes not shown on the label.
Suggested Improvement
If discussing safety, reference the exact label sections for warnings, contraindications, pregnancy/pediatric use, and dosage; clearly separate label-supported packaging information from external resources.